Evidence map›Paper›PMID 41136723›Full record

ArticleJournal of neuro-oncology2025

Navigating heterogeneity in resected brain metastases: molecular stratification and multimodal therapeutic strategies.

Xue-Fang Zhang, Ying-Zhi Liang, Hong-Yuan Wu, Jia-Luo Chen, Jiao Zhou, Yan Zhang, Xu-Wei Liang, Wen-Huan Zhong, Yuanyuan Chen

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Xue-Fang Zhang *Radiotherapy Department, Cancer Center, The Tenth Affiliated Hospital, Southern Medical University（Dongguan People's Hospital), Dongguan, 523000, China.
Ying-Zhi Liang *Radiotherapy Department, Cancer Center, The Tenth Affiliated Hospital, Southern Medical University（Dongguan People's Hospital), Dongguan, 523000, China.
Hong-Yuan Wu *Radiotherapy Department, Cancer Center, The Tenth Affiliated Hospital, Southern Medical University（Dongguan People's Hospital), Dongguan, 523000, China.
Jia-Luo ChenRadiotherapy Department, Cancer Center, The Tenth Affiliated Hospital, Southern Medical University（Dongguan People's Hospital), Dongguan, 523000, China.
Jiao ZhouRadiotherapy Department, Cancer Center, The Tenth Affiliated Hospital, Southern Medical University（Dongguan People's Hospital), Dongguan, 523000, China.
Yan ZhangRadiotherapy Department, Cancer Center, The Tenth Affiliated Hospital, Southern Medical University（Dongguan People's Hospital), Dongguan, 523000, China.
Xu-Wei LiangRadiotherapy Department, Cancer Center, The Tenth Affiliated Hospital, Southern Medical University（Dongguan People's Hospital), Dongguan, 523000, China.
Wen-Huan ZhongDepartment of Radiation Oncology, State Key Laboratory of Oncology In South China, Guangdong Provincical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, P. R. China. Zhongwh@sysucc.org.cn.
Yuanyuan ChenDepartment of Radiation Oncology, State Key Laboratory of Oncology In South China, Guangdong Provincical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, P. R. China. chenyy2@sysucc.org.cn.

Funding

Dongguan Science and technology of social development Program 20231800935742Guangdong Sci-tech Commissoner 20211800500322The Fundamental Researche Funds for the Central Universities, Sun Yat-sen University 2022008The Oncology Clinical Research Incubation Program of Dongguan People' s Hospital Z202405
6 · The paper itself

Abstract

purposeResection of brain metastases mitigates mass effect and herniation risk while extending overall survival. This cohort study characterizes recurrence-pattern-specific predictors after resection.

methodsThis retrospective multicenter study analyzed patients undergoing brain metastasis resection at two academic hospitals (June 2011-April 2022). Recurrence patterns were classified as: cavity recurrence (CR), distant intracranial progression (DICP), leptomeningeal disease (LMD), and overall intracranial progression (ICP). Survival outcomes were assessed via Kaplan-Meier method; independent prognostic factors identified by multivariate Cox regression.

resultsMedian overall survival was not reached (95% CI: 66.8-NR). Median times to progression were: ICP 14.8 months (11.5–18.5), CR 27.7 months (23.2-NR), DICP 18.2 months (15.7–24.8), LMD 46.9 months (26.4-NR). Postoperative radiotherapy(PORT) reduced CR risk (HR = 0.42, p < 0.005), particularly within 3 months (HR = 0.49, p = 0.024) and with whole-brain boost (HR = 0.30, p = 0.024). Oncogene-targeted agents(OGTA) consistently lowered all recurrence risks (CR/DICP/LMD/ICP HR: 0.35–0.54, p < 0.05). Key risk factors included age (HR = 1.03/year), infratentorial location (HR = 1.74), and extracranial metastases (HR = 1.68).

conclusionOGTA significantly reduces overall intracranial recurrence, while PORT provides substantial protection against CR. Standardized multimodal protocols are essential during the perioperative period.

Indexed as

Brain NeoplasmsNeoplasm Recurrence, LocalAdultAgedCombined Modality TherapyFemaleFollow-Up StudiesHumansMaleMiddle AgedPrognosisRetrospective StudiesBrain metastasesMetastasisPrognostic factorsRecurrence patternSurgery

Identifiers

PMID41136723

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.